Phase Scientific initiated a prospective clinical study in China to assess the effectiveness of its urine-based human papillomavirus (HPV) DNA test for cervical cancer screening, targeting up to 17,000 women. The study also evaluates urine-based methylation assays and AI-powered colposcopy image analysis. Aiming to complement HPV vaccination programs recently adopted nationwide, the noninvasive test combines advanced sample processing to improve biomarker detection. This approach could enhance cervical cancer screening accessibility and precision.